logo
Understanding Gaps in OS Data for Melanoma Adjuvant Therapy

Understanding Gaps in OS Data for Melanoma Adjuvant Therapy

Medscape28-05-2025
This transcript has been edited for clarity.
Welcome back, everybody. My name is Teresa Amaral, and it's a real pleasure to have you here for this melanoma series on Medscape. We have talked in the last two episodes about the current status of adjuvant therapy and its benefit in patients with stage III melanoma, and in the last episode we discussed the absence of overall survival (OS) benefit.
You may question why it is important to have this discussion in terms of the absence of OS benefit or the absence of data on the OS benefit. This absence of data might have three consequences, and I'm going to go through them with you.
The first one is associated with reimbursement. The fact that we will need to wait until 2028, most likely, to evaluate the OS benefit from adjuvant therapy compared to placebo in stage III might lead to some discussions in terms of the reimbursement and might lead some agencies to consider whether they would like to continue reimbursing this therapy or not in this setting.
Second, in some countries, the absence of OS data is leading to discussions on whether they will fund this therapy or not until there is clear proof that there is an OS benefit.
The third point is related to the fact that we don't knowthe patient's individual benefit. We also know that, depending on the stage, we might need to treat more patients to actually have one patient to prevent a recurrence.
For example, we know that in patients in stage IIB, we will have to treat between five and nine patients in stage IIB to prevent a recurrence. In patients with stage IIC, we need to treat between four and seven patients to prevent a recurrence.
All of these cost-effectiveness analyses are being done by the healthcare agencies, and this obviously needs to be taken into consideration when we are discussing these types of therapiesthat have a benefit in terms of relapse-free survival and distant metastasis-free survival but lack data in terms of OS benefit.
Another point is that, despite the fact that all the guidelines have been supporting the use of this therapy in stage III and stage IV — namely the ESMO guidelines and the ASCO guidelines— there is some uncertainty in terms of the OS benefit. This may lead to some difficult discussions and a lack of clear direction in terms of whatpatients should do when they need to make a decision on receiving adjuvant therapy or not.
The patients and their treating physicians may struggle with treatment choices due to this uncertainty and the fact that they don't know if there will be a long-term survival impact for this particular patient or not.
Here, we come to the first discussion that we had a couple of sessions before, which is the absence of prognostic and predictive biomarkers in this setting. Besides that, we really don't know the impact of these adjuvant treatments in terms of long-term benefitwhen we talk about OS, which might lead to reduced use of these therapies in stage III and stage II. This decline in terms of use of these adjuvant therapies has already been seen in some countries, like in Denmark.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Centene (CNC) Falls 11.1% on Investor Caution Ahead of Q2
Centene (CNC) Falls 11.1% on Investor Caution Ahead of Q2

Yahoo

timean hour ago

  • Yahoo

Centene (CNC) Falls 11.1% on Investor Caution Ahead of Q2

We recently published Centene Corporation (NYSE:CNC) is one of this week's top performers. Centene fell by 11.1 percent week-on-week, from $31.44 on July 11 to $27.95 last Friday—a new all-time low, as investors turned cautious ahead of its second quarter earnings results, further dampened by one of its peers' dismal earnings performance. During the week, its fellow insurer Elevance Health, reported a 24.2-percent drop in net income during the second quarter of the year and updated its outlook to reflect elevated medical cost trends under the Affordable Care Act and slower rate alignment in Medicaid, both of which are also being offered by Centene Corporation (NYSE:CNC). Last month, Centene Corporation (NYSE:CNC) withdrew its 2025 earnings forecast due to an expected slump in its revenues from commercial plans under the ACA or Obamacare. The withdrawal triggered a review from credit ratings issuer S&P Global Ratings, saying that it is likely to set the company's status to 'junk.' A doctor holding a clipboard in a hospital ward, discussing patient treatment plan with the nurses. 'With the removal of earnings guidance, we have less immediate clarity and confidence on the company's capital adequacy trajectory, as well as the overall strength of its business and execution capabilities,' S&P said. While we acknowledge the potential of CNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Elevance Health (ELV) Drops 18.66% After Dismal Q2 Earnings
Elevance Health (ELV) Drops 18.66% After Dismal Q2 Earnings

Yahoo

timean hour ago

  • Yahoo

Elevance Health (ELV) Drops 18.66% After Dismal Q2 Earnings

We recently published Elevance Health, Inc. (NYSE:ELV) is one of this week's top performers. Elevance Health fell by 18.66 percent week-on-week to close at $277.09 on Friday versus $340.67 a week earlier following dismal earnings performance in the second quarter of the year. In its earnings release, Elevance Health, Inc. (NYSE:ELV) said net income during the period dropped by 24.2 percent to $1.744 billion from $2.301 billion in the same period last year, pushing its six-month net earnings lower by 13.7 percent to $3.928 billion from $4.55 billion year-on-year. Revenues for the second quarter, however, increased by 13.4 percent to $49.776 billion from $43.886 billion year-on-year, while revenues for the first half of the year grew by 14.1 percent to $98.667 billion from $86.463 billion year-on-year. A medical professional working at a computer, utilizing the company's digital solutions to improve care quality for consumers. Looking ahead, Elevance Health, Inc. (NYSE:ELV) also lowered its guidance amid elevated medical cost trends in Obamacare and slower rate alignment in Medicaid. Given the industry-wide impact of elevated cost trends, the company said it now expects 2025 GAAP net income per diluted share to be approximately $24.10 and adjusted net income per diluted share to be approximately $30. While we acknowledge the potential of ELV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio

Why Medical Tourism Can Make More Sense Than US Care
Why Medical Tourism Can Make More Sense Than US Care

Medscape

timean hour ago

  • Medscape

Why Medical Tourism Can Make More Sense Than US Care

This transcript has been edited for clarity. Who out there has seen the movie Super Size Me , where the late, great Morgan Spurlock eats only McDonald's for 30 days? If you haven't seen it, you should. It's wild. Anyway, Spurlock uses this type of experience-based filmmaking to also teach us about value-based healthcare in his show Inside Man , when he goes to Thailand to get worked up for knee pain. Spurlock, like so many Americans, especially those with musculoskeletal injuries, thought he needed an elective procedure. He called all these clinics around New York City, but he wasn't finding much transparency in prices. What he did learn was that the costs were all over the place and there were long wait times. Instead, he plays medical tourism and goes to Thailand to get his care. The Price of Clarity: What $4300 Gets You Abroad For $400 and in only 1 day, he got two expert consultations, an MRI, and found out that he did not need surgery. Spurlock went even further and got more lab work, a cardiac stress test, a capsule colonoscopy, and more consultations. The entire thing, including airfare and accommodations, cost him $4300. What can you get in American healthcare with $4300? It wouldn't include a trip to Thailand. [ Sigh ] Medical tourism. Now, granted, Spurlock was overseas, but this is the definition of value-based care. He had transparent, seamless, coordinated care with the focus on outcomes and not just volume. Over here, it's a completely different story. Meet Mya Neehurtz: A Very American Healthcare Story I came across an email titled "The Surgeon's Record," by editor-in-chief Dr Ben Schwartz, that goes through a hypothetical case showing just how fragmented and complex musculoskeletal care can be. In the post, which can be viewed on his Dem Dry Bones Substack, there's a fictional character named Mya Neehurtz (a great name) who has knee pain, similar to Morgan Spurlock and millions of Americans. The hypothetical journey goes like this. Mya sees her PCP for knee pain, who orders an ultrasound and an x-ray, and obviously, she faces two facility fees because the imaging center is not where her doctor is. Some of the results show bone arthritis and a potential bone mass. The PCP is like, This isn't my area of expertise. Let's order an MRI and get your referral to an orthopedic surgeon . Well, all the surgeons are busy. She can't get in for months unless she goes out of network, so she pays out of pocket. The surgeon is like, Wait, I can't access these images because the systems don't communicate. Also, why did your doctor order all these tests? This is all while the surgeon is really backlogged, so he reorders some images and tries Mya out on noninvasive treatments. Her knee pain continues, and finally, after months, she gets a knee replacement. Examples like this happen all the time in American healthcare with chronic and acute illnesses. In Mya's case, in this example, there's a lack of shared decision-making, there's poor access to subspecialists, and evidence-based guidelines may or may not be followed. Even the technology isn't properly communicating, and I know you could probably relate with this. I see these barriers that happen with patient care all the time. What Is Value-Based Care, Really? Value-based care isn't just a buzzword. According to many experts, including those at the Commonwealth Fund, value-based care is all about getting patients the right care at the right time, while minimizing all these unnecessary and fragmented steps. Value-based care ties provider payments with the quality of care performed, with additional focuses on cost efficiency and equity. Improving health outcomes while reducing waste — what a win. Who wouldn't want that? Now, the Centers for Medicare & Medicaid Services (CMS) has several value-based programs in place, including the End-Stage Renal Disease Quality Incentive Program, Hospital Readmissions Reduction Program, and the Hospital-Acquired Condition Reduction Program. And these programs have three goals in mind: Better care for individuals Better health for populations Lowering cost Lower cost — what a concept. According to a 2019 JAMA article, up to $935 billion is wasted annually on unnecessary services. If you look at this example from Dr Schwartz and then you amplify it across all states and include many more conditions, you can see how this adds up to a large amount of money and time wasted. So, What's Holding Us Back? I agree with Dr Ben Schwartz when he says that we have the capability to have these integrated medical clinics right here. They don't have to just be medical tourism fairytales of places like Thailand. We can have all-inclusive surgery centers that have state-of-the-art, digital health support, and that have everything you need under one roof, including subspecialists you may refer to — imaging, PT, OT, lab work, and more. For now, this seems like the diamond-in-the-rough exception and not the rule. Yes, we need more advocacy and lobbying. As suggested by Dr Maria Ansari in an article posted on the AMA website , we need more data looking at health disparities and actionable items, and then we could potentially follow a payment playbook that involves identifying the right patient population, good benchmarks, and then having transparent feedback. The reality is that we have all the parts to the solution; we just need to put the puzzle together. Now, I'm obviously simplifying a very complex system that is rooted in bureaucracy, but who am I? I'm just a burned-out physician. I'm not a health policy researcher. I want to hear from all of you. How far are we, really, from having a more efficient, value-based healthcare system? What are the barriers? Are there any initiatives that you have come across that work? Comment below.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store